• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cronos Group Inc. to Hold 2026 Second Quarter Earnings Conference Call on August 6, 2026

    7/16/26 7:30:00 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $CRON alert in real time by email

    TORONTO, July 16, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2026 second quarter earnings conference call on Thursday, August 6, 2026 at 8:30 a.m. ET. Cronos’ senior management team will discuss the Company’s financial results and will be available for questions from the investment community after prepared remarks.

    To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay on the Company’s website.

    About Cronos

    Cronos is a global cannabis company focused on scaling leading consumer goods products through R&D and innovation. With a passion to responsibly elevate the consumer experience, Cronos is building an iconic brand portfolio. Cronos’ diverse international brand portfolio includes Spinach®, PEACE NATURALS®, LIT™ and Lord Jones®. For more information about Cronos and its brands, please visit: https://thecronosgroup.com/.

    Forward-looking Statements

    This press release may contain information that may constitute "forward-looking information" or "forward-looking statements" within the meaning of applicable Canadian and U.S. securities laws and court decisions (collectively, "Forward-looking Statements"). All information contained herein that is not clearly historical in nature may constitute Forward-looking Statements. In some cases, Forward-looking Statements can be identified by the use of forward-looking terminology such as "may", "will", "expect", "plan", "anticipate", "intend", "potential", "estimate", "believe" or the negative of these terms, or other similar expressions intended to identify Forward-looking Statements. Some of the Forward-looking Statements contained in this press release include statements about Cronos’ intention to build an iconic brand portfolio and its focus on scaling leading consumer goods products through R&D and innovation. Forward-looking Statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive risks, financial results, results, performance or achievements expressed or implied by those Forward-looking Statements and the Forward-looking Statements are not guarantees of future performance. A discussion of some of the material risks applicable to the Company can be found in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, each of which have been filed on SEDAR+ and EDGAR and can be accessed at www.sedarplus.ca and www.sec.gov/edgar, respectively. Any Forward-looking Statement included in this press release is made as of the date of this press release and, except as required by law, Cronos disclaims any obligation to update or revise any Forward-looking Statement. Readers are cautioned not to put undue reliance on any Forward-looking Statement.

    Cronos Contact

    Harrison Aaron

    Investor Relations

    Tel: (416) 504-0004

    investor.relations@thecronosgroup.com



    Primary Logo

    Get the next $CRON alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRON

    DatePrice TargetRatingAnalyst
    1/27/2026Buy
    Canaccord Genuity
    11/2/2022$3.00Mkt Perform
    Bernstein
    7/28/2022Hold → Buy
    Canaccord Genuity
    5/11/2022Neutral → Sector Outperform
    CIBC
    3/22/2022Underweight → Equal Weight
    Barclays
    3/7/2022$4.00 → $3.00Neutral
    Piper Sandler
    2/22/2022$7.00 → $4.25Sell
    Canaccord Genuity
    2/22/2022$7.00 → $4.00Neutral
    Piper Sandler
    More analyst ratings

    $CRON
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Cronos Group

    Canaccord Genuity initiated coverage of Cronos Group with a rating of Buy

    1/27/26 9:29:20 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Bernstein initiated coverage on Cronos Group with a new price target

    Bernstein initiated coverage of Cronos Group with a rating of Mkt Perform and set a new price target of $3.00

    11/2/22 6:32:18 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Cronos Group upgraded by Canaccord Genuity

    Canaccord Genuity upgraded Cronos Group from Hold to Buy

    7/28/22 9:01:16 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    $CRON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Broughton Darren Chester

    3 - Cronos Group Inc. (0001656472) (Issuer)

    6/30/26 4:06:24 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Officer Doucet Terrence Gregory Joseph converted options into 10,597 shares and covered exercise/tax liability with 5,199 shares, increasing direct ownership by 5% to 110,588 units (SEC Form 4)

    4 - Cronos Group Inc. (0001656472) (Issuer)

    5/14/26 4:58:49 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Officer Wagner Adam converted options into 10,367 shares, increasing direct ownership by 11% to 103,987 units (SEC Form 4)

    4 - Cronos Group Inc. (0001656472) (Issuer)

    5/14/26 4:58:02 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    $CRON
    SEC Filings

    View All

    Cronos Group Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Cronos Group Inc. (0001656472) (Filer)

    6/22/26 5:04:19 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-Q filed by Cronos Group Inc.

    10-Q - Cronos Group Inc. (0001656472) (Filer)

    5/11/26 7:33:01 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Cronos Group Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - Cronos Group Inc. (0001656472) (Filer)

    5/11/26 7:32:00 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    $CRON
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cronos’ SOURZ by Spinach® Expands its Lineup of Edibles

    TORONTO, July 21, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos"), an innovative global cannabis company, is expanding its lineup of SOURZ by Spinach® Fully Blasted multipacks to meet consumer demand for edible products during the summer season. The lineup of SOURZ by Spinach® Fully Blasted multipacks with liquid diamond-infused gummies now includes the brand’s popular flavors featuring rare cannabinoid formulations, along with a new limited-time offer (LTO) flavor for the summer months. SOURZ by Spinach® Fully Blasted multipacks are the #1 edible multipack in Canada, capturing 31.7% share of all 10x10 pack sales in May 2026¹. The Spinach® brand continues to

    7/21/26 7:30:00 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Cronos Group Inc. to Hold 2026 Second Quarter Earnings Conference Call on August 6, 2026

    TORONTO, July 16, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2026 second quarter earnings conference call on Thursday, August 6, 2026 at 8:30 a.m. ET. Cronos’ senior management team will discuss the Company’s financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay o

    7/16/26 7:30:00 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Cronos Announces Appointment of ATB Cormark as its Broker for Share Repurchases in Canada

    TORONTO, June 30, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. ("Cronos" or the "Company") (NASDAQ:CRON) (TSX:CRON), an innovative global cannabis company, announced today that it has appointed ATB Capital Markets Corp. ("ATB Cormark") to act as its broker in connection with share repurchases over the facilities of the TSX or other alternative Canadian trading systems, in place of Virtu Canada Corp., under its previously announced share repurchase program. About Cronos Cronos is a global cannabis company focused on scaling leading consumer goods products through research and development and innovation. With a passion to responsibly elevate the consumer experience, Cronos is building an ico

    6/30/26 5:15:00 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    $CRON
    Leadership Updates

    Live Leadership Updates

    View All

    Cronos Announces Appointment of ATB Cormark as its Broker for Share Repurchases in Canada

    TORONTO, June 30, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. ("Cronos" or the "Company") (NASDAQ:CRON) (TSX:CRON), an innovative global cannabis company, announced today that it has appointed ATB Capital Markets Corp. ("ATB Cormark") to act as its broker in connection with share repurchases over the facilities of the TSX or other alternative Canadian trading systems, in place of Virtu Canada Corp., under its previously announced share repurchase program. About Cronos Cronos is a global cannabis company focused on scaling leading consumer goods products through research and development and innovation. With a passion to responsibly elevate the consumer experience, Cronos is building an ico

    6/30/26 5:15:00 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Cronos Group Inc. Announces Results of 2026 Annual Meeting of Shareholders

    TORONTO, June 22, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") today announced that at its Annual Meeting of Shareholders held on Thursday, June 18, 2026 (the "Meeting"), shareholders holding a total of 271,828,759 common shares of the Company voted in person or by proxy, representing 72.24% of the total number of common shares of the Company outstanding. Each of the directors listed as a nominee in the Company’s definitive proxy statement dated April 24, 2026, was elected as a director of the Company, with each director receiving in excess of 93.6% of the votes cast in favor of his or her election. The detailed results of the vote for th

    6/22/26 5:30:00 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Cronos Group Inc. Announces Results of 2025 Annual Meeting of Shareholders

    TORONTO, June 23, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") today announced that at its Annual Meeting of Shareholders held on Friday, June 20, 2025 (the "Meeting"), shareholders holding a total of 276,989,452 common shares of the Company voted in person or by proxy, representing 71.87% of the total number of common shares of the Company outstanding. Each of the directors listed as a nominee in the Company's definitive proxy statement dated April 25, 2025 was elected as a director of the Company, with each director receiving in excess of 92.3% of the votes cast in favor of his or her election. The detailed results of the vote for the e

    6/23/25 5:30:00 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    $CRON
    Financials

    Live finance-specific insights

    View All

    Cronos Group Inc. to Hold 2026 Second Quarter Earnings Conference Call on August 6, 2026

    TORONTO, July 16, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2026 second quarter earnings conference call on Thursday, August 6, 2026 at 8:30 a.m. ET. Cronos’ senior management team will discuss the Company’s financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay o

    7/16/26 7:30:00 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Cronos Group Inc. to Hold 2026 First Quarter Earnings Conference Call on May 11, 2026

    TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2026 first quarter earnings conference call on Monday, May 11, 2026 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay on th

    4/20/26 7:30:00 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    Cronos Group Inc. to Hold 2025 Fourth Quarter and Full-Year Earnings Conference Call on February 26, 2026

    TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ:CRON) (TSX:CRON) ("Cronos" or the "Company") will hold its 2025 fourth quarter and full-year earnings conference call on Thursday, February 26, 2026 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks. To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be arch

    2/12/26 7:30:00 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    $CRON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Cronos Group Inc. (Amendment)

    SC 13D/A - Cronos Group Inc. (0001656472) (Subject)

    4/25/24 6:39:55 PM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13D/A filed by Cronos Group Inc. (Amendment)

    SC 13D/A - Cronos Group Inc. (0001656472) (Subject)

    12/19/22 8:47:03 AM ET
    $CRON
    Medicinal Chemicals and Botanical Products
    Health Care